ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts

International Journal of Cancer

Volumn 72, Issue 3, 1997, Pages 416-423

  De Witte, Hans ^a   Pappot, Helle ^b   Brünner, Nils ^b   GrØndahl Hansen, Jan ^b   HØyer Hansen, Gunilla ^b   Behrendt, Niels ^b   Guldhammer Skov, Birgit ^c   Sweep, Fred ^a   Benraad, Theo ^a   DanØ, Keld ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FINSEN LABORATORY   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE EXTRACT; UROKINASE; UROKINASE RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CROSS-LINKING REAGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSORBENT TECHNIQUES; LUNG NEOPLASMS; MICE; RABBITS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030744417     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970729)72:3<416::AID-IJC8>3.0.CO;2-S     Document Type: Article

References (39)

1. BEHRENDT, N., PLOUG, M., RØNNE, E., HØYER-HANSEN, G. and DANØ, K., Cellular receptor for urokinase-type plasminogen activator: protein structure. Methods Enzymol., 223, 207-222 (1993a).
2. 2-terminal umino acid sequence and glycosylation variants. J. biol. Chem., 265, 6453-6460 (1990).
3. BEHRENDT, N., RØNNE, E. and DANØ, K., Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. biol. Chem., 268, 5985-5989 (1993b).
4. BLASI, R. VASSALI, J.-D. AND DANØ, K., Urokinase-type plasminogen activator: pro-enzyme, receptor, and inhibitors. J. Cell Biol., 104, 801-804 (1987).
5. BRADFORD, MM., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
6. CAMIOLO, S.M., SUITA, M.R. and MADEJA, J.M., Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem., 12, 297-305 (1982).
7. DANØ, K., ANDREASEN, P.A., GRØNDAHL-HANSEN, J., KRISTENSEN, P., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-166 (1985).
8. DANØ, K., BEHRENDT, N., BRÜNNER, N., ELLIS, V., PLOUG, M. and PYKE, C., The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8, (Suppl. 1), 189-203 (1994).
9. DUFFY, M.J., The role of proteolytic enzymes in cancer invasion and metastasis. Clin. exp. Metastasis, 10, 145-155 (1992).
10. ELLIS, V., PYKE, C., ERIKSEN, J., SOLBERG, H. and DANØ, K., The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N.Y. Acad. Sci., 667, 13-31 (1992).
11. GOODSON, R.J., DOYLE, M.V., KAUFMAN, S.E. and ROSENBERG, S., High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. nat. Acad. Sci. (Wash.), 91, 7129-7133 (1994).
12. GRØNDAHL-HANSEN, J., CHRISTENSEN, I.J., ROSENQUJIST, C., BRÜNNER, N., MOURIDSEN, H.T., DANØ, K. and BLICHERT-TOFT, M., High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521 (1993).
13. GRØNDAHL-HANSEN, J., PETERS, H.A., VAN PUTTEN, W.L.J., LOOK, M.P., PAPPOT, H., RØNNE, E., DANØ, K., KLIJN, J.G.M., BRÜNNER, N. and FOEKENS, J.A., Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res., 1, 1079-1087 (1995).
14. GRØNDAHL-HANSEN, J., RALFKIAER, E., KIRKEBY, L.T., KRISTENSEN, P., LUND, L.R. and DANØ, K., Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Amer. J. Pathol., 138, 111-117 (1991).
15. HASUI, Y. MARUTSUKA, K., ASADA, Y. and OSADA, Y., Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology, 47, 34-37 (1996).
16. HOYER-HANSEN, G., RØNNE, E., SOLBERG, H., BEHRENDT, N., PLOUG, M., LUND, L.R., ELLIS, V. and DANØ, K., Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligund binding domain. J. biol. Chem., 267, 18224-18229 (1992).
17. KALTOFT, K., NIELSEN, L.S., ZEUTHEN, J. and DANØ, K., Monoclonal antibody that specifically inhibits a human Mr ≈ 52,000 plasminogen activating enzyme. Proc. nat. Acad. Sci. (Wash.), 79, 3720-3723 (1982).
18. MIGNATTI, P. and RIFKIN, D.B., Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195 (1993).
19. r receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J. biol. Chem., 263, 2358-2363 (1988).
20. OSSOWSKI, L., In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107, 2437-2445 (1988).
21. OSSOWSKI, L., CLUNIE, G., MASUCCI, M. and BLASI, F., In vivo paracrine interaction between urokinuse and its receptor: eftect on tumor cell invasion. J. Cell Biol., 115, 1107-1112 (1991).
22. OSSOWSKI, L. and REICH, E., Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35, 611-619 (1983).
23. PEDERSEN, H., BRÜNNER, N., FRANCIS, D., ØSTERLIND, K., RØNNE, E., HØI-HANSEN, H., DANØ, K. and GRØNDAHL-HANSEN, J., Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54, 4671-4675 (1994).
24. PETERSEN, L.C., LUND, L.R., NIELSEN, L.S., DANØ, K. and SKRIVER, L., One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. biol. Chem., 263, 11189-11195 (1988).
25. 2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator; a domain structure belonging to a novel superfamily of glycolipid anchored membrane proteins. J. biol. Chem., 268, 17539-17556 (1993).
26. PLOUG, M., ELLIS, V. and DANØ, K., Ligand interaction between urokinase-type plasminogen activator and its inhibitor probed with 8-anilino-1-naphtalenesulfonate; evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry, 33, 8991-8997 (1994).
27. PÖLLäNEN, J., STEPHENS, R.W. and VAHERI, A., Plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res., 57, 273-328 (1991).
28. PYKE, C., GRAEM, N., RALFKIAER, E., RØNNE, E., HØYER-HANSEN, G., BRÜNNER, N. and DANØ, K., The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53, 1911-1915 (1993).
29. PYKE, C., KRISTENSEN, P., RALFKIAER, E., GRØNDAHL-HANSEN, J., ERIKSEN, J., BLASI, F. and DANØ, K., Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Amer. J. Pathol., 138, 1059-1067 (1991).
30. QUAX, P.H.A., PEDERSEN, N., MASUCCI, M.T., WEENING-VERHOEFF, E.J.D., DANØ, K., VERHEIJEN, J.H. and BLASI, F., Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell. Regul., 2, 793-803 (1991).
31. RETTENBERGER, P., WILHELM, O., OI, H., WEIDLE, U., GORETZKI, L., KOPPITZ, M., LOTTSPEICH, F., KÖNIG, B., PESSARA, U., KRAMER, M.D., SCHMITT, M. und MAGDOLEN, V., A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Biol. Chem. Hoppe Seyler 376, 587-594 (1995).
32. 2-terminal domain of the urokinase receptor. FEBS Lett., 288, 233-236 (1991).
33. RØNNE, E., HØYER-HANSEN, G., BRÜNNER, N., PEDERSEN, H., RANK, F., OSBORNE, C.K., CLARK, G.M., DANØ, K. and GRØNDAHL-HANSEN, J., Urokinase receptor in breast cancer tissue extracts; enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res. Treat., 33, 199-207 (1995).
34. ROSENQUIST, C., THORPE, S.M., DANØ, K. and GRØNDAHL-HANSEN, J., Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res. Treat., 28, 223-229 (1993).
35. SAPPINO, A.P., BELIN, D., HUARTE, J., HIRSCHELSCHOLZ, S., SAURAT, J.H. and VASSALLI, J.D., Differential protease expression by cutaneous squamous and basal cell carcinomas. J. clin. Invest., 88, 1073-1079 (1991).
36. SCHULMAN, M., WILDE, C.D. and KÖHLER, G.A., A better cell line for making hybridomas secreting specific antibodies. Nature (Lond.), 275, 269-270 (1978).
37. SOLBERG, H., RØMER, J., BRÜNNER, N., HOLM, A., SIDENIUS, N., DANØ, K. and HØYER-HANSEN, G., A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer, 58, 877-881 (1994).
38. THORPE, S.M., Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res. Treat., 9, 175-189 (1987).
39. VERSPAGET, H.W., SIER, C.F., GANESH, S., GRIFFIOEN, G. and LAMERS, C.B., Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Europ. J. Cancer, 31 A, 1105-1109 (1995).